Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Paul Linh Nguyen, M.D.

Co-Author

This page shows the publications co-authored by Paul Nguyen and Stuart Lipsitz.
Connection Strength

1.865
  1. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urol Oncol. 2015 Feb; 33(2):69.e29-34.
    View in: PubMed
    Score: 0.150
  2. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011 Apr 20; 29(12):1517-24.
    View in: PubMed
    Score: 0.119
  3. Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Netw Open. 2020 03 02; 3(3):e201839.
    View in: PubMed
    Score: 0.055
  4. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):410-418.
    View in: PubMed
    Score: 0.054
  5. Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. J Natl Compr Canc Netw. 2019 09 01; 17(9):1049-1058.
    View in: PubMed
    Score: 0.053
  6. The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals? Urol Oncol. 2019 09; 37(9):575.e9-575.e18.
    View in: PubMed
    Score: 0.052
  7. Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 04; 201(4):735-741.
    View in: PubMed
    Score: 0.052
  8. Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. J Urol. 2019 04; 201(4):728-734.
    View in: PubMed
    Score: 0.052
  9. Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329.
    View in: PubMed
    Score: 0.051
  10. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Ann Surg Oncol. 2019 Jan; 26(1):297-305.
    View in: PubMed
    Score: 0.051
  11. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019 03; 22(1):125-136.
    View in: PubMed
    Score: 0.050
  12. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018 09; 200(3):573-581.
    View in: PubMed
    Score: 0.049
  13. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229.
    View in: PubMed
    Score: 0.048
  14. Variation in the use of active surveillance for low-risk prostate cancer. Cancer. 2018 Jan 01; 124(1):55-64.
    View in: PubMed
    Score: 0.047
  15. Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. Eur Urol. 2018 Mar; 73(3):445-451.
    View in: PubMed
    Score: 0.046
  16. The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICAREĀ® Military Database. J Urol. 2017 12; 198(6):1295-1300.
    View in: PubMed
    Score: 0.046
  17. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487.
    View in: PubMed
    Score: 0.045
  18. Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536.
    View in: PubMed
    Score: 0.044
  19. Determinants of cancer screening in Asian-Americans. Cancer Causes Control. 2016 08; 27(8):989-98.
    View in: PubMed
    Score: 0.043
  20. The influence of marital status on the use of breast, cervical, and colorectal cancer screening. Prev Med. 2016 08; 89:140-145.
    View in: PubMed
    Score: 0.043
  21. Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. J Urol. 2016 Oct; 196(4):1090-5.
    View in: PubMed
    Score: 0.042
  22. Data on Medicare eligibility and cancer screening utilization. Data Brief. 2016 Jun; 7:679-81.
    View in: PubMed
    Score: 0.042
  23. The impact of Medicare eligibility on cancer screening behaviors. Prev Med. 2016 Apr; 85:47-52.
    View in: PubMed
    Score: 0.041
  24. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol. 2016 Jan; 2(1):85-93.
    View in: PubMed
    Score: 0.041
  25. Population-based comparative effectiveness of salvage radical prostatectomy vs cryotherapy. Urology. 2014 Mar; 83(3):653-7.
    View in: PubMed
    Score: 0.036
  26. Population-based determinants of radical prostatectomy operative time. BJU Int. 2014 May; 113(5b):E112-8.
    View in: PubMed
    Score: 0.036
  27. Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. Urol Oncol. 2014 Apr; 32(3):303-8.
    View in: PubMed
    Score: 0.036
  28. Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy. BJU Int. 2013 Jun; 111(8):1208-14.
    View in: PubMed
    Score: 0.034
  29. Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int. 2013 Aug; 112(4):E273-80.
    View in: PubMed
    Score: 0.034
  30. Certificate of need programs, intensity modulated radiation therapy use and the cost of prostate cancer care. J Urol. 2013 Jan; 189(1):75-9.
    View in: PubMed
    Score: 0.033
  31. Influence of surgeon and hospital volume on radical prostatectomy costs. J Urol. 2012 Dec; 188(6):2198-202.
    View in: PubMed
    Score: 0.033
  32. Morbidity and costs of salvage vs. primary radical prostatectomy in older men. Urol Oncol. 2013 Nov; 31(8):1477-82.
    View in: PubMed
    Score: 0.032
  33. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol. 2012 Jun; 61(6):1239-44.
    View in: PubMed
    Score: 0.032
  34. Hospital volume, utilization, costs and outcomes of robot-assisted laparoscopic radical prostatectomy. J Urol. 2012 May; 187(5):1632-7.
    View in: PubMed
    Score: 0.032
  35. Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer. BJU Int. 2012 Jul; 110(2 Pt 2):E92-8.
    View in: PubMed
    Score: 0.031
  36. Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer. 2012 Mar 01; 118(5):1260-7.
    View in: PubMed
    Score: 0.031
  37. Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes. Eur Urol. 2011 Sep; 60(3):536-47.
    View in: PubMed
    Score: 0.030
  38. Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology. 2011 Jul; 78(1):93-8.
    View in: PubMed
    Score: 0.030
  39. Overuse of imaging for staging low risk prostate cancer. J Urol. 2011 May; 185(5):1645-9.
    View in: PubMed
    Score: 0.030
  40. Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer. 2011 Nov 01; 117(21):4846-54.
    View in: PubMed
    Score: 0.030
  41. Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. Urology. 2011 Feb; 77(2):402-6.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.